Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab IPO Summary
Symbiotec Pharmalab IPO opens for subscription on 24 Aug 2026 and closes on 27 Aug 2026.The IPO will be listed on NSE, BSE with the tentative listing date set for 01 Sep 2026.
Symbiotec Pharmalab IPO price band has been fixed at ₹938 – ₹988 per share. The face value is ₹2 per share with a lot size of 15.
Symbiotec Pharmalab IPO total issue size comprises 1,77,86,442 shares (aggregating up to ₹1757.30 Cr). This includes a fresh issue of 15,21,261 shares (aggregating up to ₹150.30 Cr). Offer for Sale consists of 1,62,65,181 shares (aggregating up to ₹1607.00 Cr). Pre-issue shareholding stands at 6,16,81,496, which will increase to 6,32,02,757 post-issue.
Symbiotec Pharmalab IPO carries a ₹185 (18.72%) GMP, reflecting investor sentiment.
Symbiotec Pharmalab IPO Lot Size :Retail Minimum is 1 lot (15 shares) amounting to ₹14,820. Retail Maximum is 13 lots (195 shares) amounting to ₹1,92,660. SHNI Minimum is 14 lots (210 shares) amounting to ₹2,07,480. SHNI Maximum is 67 lots (1,005 shares) amounting to ₹9,92,940. BHNI Minimum is 68 lots (1,020 shares) amounting to ₹10,07,760.
Symbiotec Pharmalab IPO Details
Symbiotec Pharmalab IPO Subscription
Symbiotec Pharmalab IPO Application Wise Breakup (Approx)
Symbiotec Pharmalab IPO Dates
- 24 Aug 2026Opening dateOpen
- 27 Aug 2026Closing dateClose
- 28 Aug 2026Allotment Date Allotment
- 31 Aug 2026Initiation of RefundsRefund
- 31 Aug 2026Credit of SharesCredit
- 01 Sep 2026Listing dateListing
Symbiotec Pharmalab IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| SHNI Minimum | 14 | 210 | ₹2,07,480 |
| SHNI Maximum | 67 | 1005 | ₹9,92,940 |
| BHNI Minimum | 68 | 1020 | ₹10,07,760 |
Symbiotec Pharmalab IPO Reservation
Promoter Holding
Documents
Symbiotec Pharmalab IPO Valuations
Symbiotec Pharmalab Financial Information
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
| Amount in ₹ Crore | |||
About Symbiotec Pharmalab IPO
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
Strength Of Symbiotec Pharmalab IPO
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and global customer base.
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.
- Continuous investment in R&D, with leading technological capabilities among Indian peers.
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.
Risk Of Symbiotec Pharmalab IPO
- We derive almost all of our revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, our top five APIs constituted 62.27%, 63.16% and 60.37% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and our top products in particular, or disruption in production, could have an adverse effect on our business, results of operations, financial condition and cash flows.
- Our manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and our customers. Any manufacturing or quality control failures may subject us to regulatory action, damage our reputation and have an adverse effect on our business, results of operations, financial condition and cash flows.
- We export our products to various countries and our revenue from external customers outside India as per Ind AS 108 - "Operating Segments" represented 67.04%, 55.19% and 59.97% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Our inability to handle risks associated with our export sales could adversely affect our sales to customers in foreign countries, our results of operations, financial condition and cash flows.
- In Fiscals 2026, 2025 and 2024, revenue from the United States represented 13.12%, 4.02% and 8.97% of our revenue from operations. The imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect our results of operations, financial condition and cash flows.
- We derive a substantial portion of our revenue from certain key customers. Revenue generated from our top ten customers accounted for 57.59%, 55.90% and 61.65% of our revenue from sale of product in Fiscals 2026, 2025 and 2024, respectively. Loss of our relationship with any of these customers or delays or reductions in their orders could have an adverse effect on our business, results of operations, financial condition and cash flows.
- Our manufacturing facilities and dedicated R&D centres are located in the state of Madhya Pradesh in India. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect our business, results of operations, financial condition and cash flows. A slowdown, interruption or shutdown in our manufacturing operations could have an adverse effect on our business, results of operations, financial condition and cash flows.
- We depend on certain suppliers for raw materials for our operations. Purchases from our top ten suppliers accounted for 25.50%, 18.41% and 50.33% of our total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect our business, results of operations, financial condition and cash flows.
- We operate in a highly competitive market. We face competition both within our API manufacturing business and in our role as a CDMO, which we have recently commenced. An inability to compete effectively may adversely affect our business, results of operations, financial condition and cash flows.
- We procure a portion of our raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing our imports from these countries, could disrupt our raw material supply and adversely affect our results of operations, financial condition and cash flows.
- Our success depends on our ability to develop and commercialise new products in a timely manner. If our research and development efforts do not succeed, or the products we commercialise do not perform as expected, the introduction of new products may be hindered, which could adversely affect our business, results of operations, financial condition and cash flows.
Objectives Symbiotec Pharmalab IPO
1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
2. General corporate purposes
Company Contact Details
Symbiotec Pharmalab Ltd. Address
385/2, Pigdamber, Rau, Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/
Registrar Contact Details
Symbiotec Pharmalab FAQs
The Symbiotec Pharmalab IPO is a MAINBOARD public issue comprising 17786442 equity shares with a face value of ₹2 each, aggregating to a total issue size of ₹1757.30 Cr. The issue price has been fixed at ₹988 per equity share, and the minimum application size is 15 shares.
The IPO opens for subscription on 24 Aug 2026, and closes on 27 Aug 2026.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹185 (18.72%).
Quick Links
Comments
